Trillium Therapeutics Welcomes Dr. Michael Moore to Board of Directors

    TORONTO, Feb. 23 /PRNewswire/ - Trillium Therapeutics Inc. (TTI)
 announced today that Dr. Michael Moore, Chief Executive Officer of PIramed,
 has joined TTI's Board of Directors.
     "The addition of Dr. Moore to TTI's Board of Directors is another
 important step in the company's quest to assemble strong and well-balanced
 leadership that blends global industry veterans with experienced investors,"
 explained Dr. Niclas Stiernholm, TTI's Chief Executive Officer. "We are very
 pleased to welcome such a seasoned biotechnology executive as Michael to the
 TTI team. His impressive scientific credentials, vast drug development
 experience, and far-reaching networks in both industry and academia, make him
 a superb addition to TTI's already high-quality Board."
     Dr. Moore is currently Chief Executive Officer and Director of PIramed
 Ltd, a privately held UK-based biotechnology company focused on the discovery
 and development of drugs targeting members of the PI3 kinase super-family. He
 is also an Associate Professor at the Brunel Institute of Cancer Genetics and
 Pharmacogenomics. Prior to joining PIramed, he held several progressive
 positions (1988-2003), including Chief Scientific Officer and Research
 Director, at Xenova Group plc, a publicly traded biotechnology company. Dr.
 Moore has held a series of academic appointments at Christie Hospital,
 Paterson Institute for Cancer Research and University of Manchester, which
 included a tenured Cancer Research Campaign Appointment as well an Honorary
 Readership in Immunology and Oncology at University of Manchester Medical
 School. He received his Ph.D. and D.Sc. degrees from Nottingham University and
 has more than 150 scientific publications.
     Trillium also announced that Dr. Bob Uger has been promoted to Vice
 President, Research & Development effective February 1, 2004.
     TTI, a privately held Research and Development (R&D) company, specializes
 in the development of innovative therapies that restore balance to the immune
 system in conditions associated with aberrant and harmful immune responses,
 such as autoimmune and inflammatory disorders, graft rejection and viral
 hepatitis. The Company identifies therapeutic candidates with promising
 preclinical profiles and advances these into clinical testing, with the
 primary objective of demonstrating safety and efficacy in humans. The Company
 has two lead development candidates, a CD200 fusion protein (CD200Fc) and an
 Fgl2-specific monoclonal antibody (Fgl2 Mab). TTI has a variety of external
 R&D collaborations, including several with major pharmaceutical and
 biotechnology companies.
 
 

SOURCE  Trillium Therapeutics Inc.